An ongoing phase II clinical trial is evaluating the activity of merestinib in NSCLC harboring MET exon 14 skipping mutations or advanced solid cancers with NTRK1–3 rearrangements (NCT02920996). This evidence concerns the gene MET and non-small cell lung carcinoma.